Interventional cardiology

Flourish Research Expands with opening of new site Bowie

Retrieved on: 
Monday, December 11, 2023
DRS, Association of Black Cardiologists, Research, De novo, Cardiology, Interventional cardiology, Cultural diversity, Doctor of Philosophy, Physician, Nursing, MD, Flourish

NEW YORK, Dec. 11, 2023 /PRNewswire-PRWeb/ -- Flourish Research announces the opening of a new Cardiology research site. Flourish - Bowie is in the metropolitan area of Baltimore, MD, and Washington DC, and expands the company's cardiovascular and metabolic therapeutic areas under the leadership of cardiologists, Barbara Hutchinson MD, PhD and Sarah Collins, MD. Dr. Hutchinson is the Chairwoman of the Board for the Association of Black Cardiologists and her practice, Chesapeake Cardiac Care, has been serving a diverse patient population since its founding in 2003.

Key Points: 
  • Flourish Research announces the opening of Flourish-Bowie, a new Cardiology research site in the metropolitan area of Baltimore, MD, and Washington DC.
  • NEW YORK, Dec. 11, 2023 /PRNewswire-PRWeb/ -- Flourish Research announces the opening of a new Cardiology research site.
  • Flourish - Bowie is in the metropolitan area of Baltimore, MD, and Washington DC, and expands the company's cardiovascular and metabolic therapeutic areas under the leadership of cardiologists, Barbara Hutchinson MD, PhD and Sarah Collins, MD.
  • Flourish Research is committed to improving diversity in clinical research and with the help of the Association of Black Cardiologists we are proud to launch our first De Novo site, bringing us closer to accomplishing this goal."

Argon Medical Launches Kodiak™ Dual Port Coaxial Introducer Kit for Complex Vascular Procedures

Retrieved on: 
Thursday, November 30, 2023
Interventional radiology, Dual-ported video RAM, Senior, Complex, Patient, Global marketing, Interventional cardiology, Caregiver, Argon, Vascular surgery, Physician, IVC, Medical imaging, Oncology

PLANO, Texas, Nov. 30, 2023 /PRNewswire/ -- Argon Medical Devices, a leading provider of device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology, announced the launch of the Kodiak™ Dual Port Coaxial Introducer Kit for precise and streamlined introduction of diagnostic and therapeutic devices into the vasculature.

Key Points: 
  • PLANO, Texas, Nov. 30, 2023 /PRNewswire/ -- Argon Medical Devices, a leading provider of device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology, announced the launch of the Kodiak™ Dual Port Coaxial Introducer Kit for precise and streamlined introduction of diagnostic and therapeutic devices into the vasculature.
  • The Kodiak Dual Port Coaxial Introducer Kit is engineered for versatility, as it applies to various vascular procedures.
  • In doing so, Kodiak can simplify complex procedures where the rigor of the procedures demands a robust device to provide treatment efficiently.
  • "The Kodiak Dual Port Coaxial Introducer Kit offers unmatched versatility and robustness, applicable to a variety of complex endovascular procedures that require simultaneous introduction of multiple components into the vasculature.

Patient Engagement, Digital Therapeutics and Social Determinants of Health in Cardiometabolic Drug Development, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, November 16, 2023
World Health Organization, Food, Entrepreneurship, WHO, Patient, Social, FDA, Obesity, Food and Drug Administration, Interventional cardiology, Health, Therapy, Harvard Medical School, Moyamoya disease, Medical device, Nursing, Medicine

TORONTO, Nov. 16, 2023 /PRNewswire-PRWeb/ -- In this informative webinar, discover strategies for patient engagement and digital therapeutics relating to the management of social determinants of health in cardiometabolic diseases and recent Food and Drug Administration (FDA) guidance on the future of Lupus research.

Key Points: 
  • Attendees will learn how behavioral science instruments can be deployed in development programs to characterize social determinants of health.
  • The featured speakers will discuss avenues for how digital therapeutics can be developed to mitigate aspects of social determinants of health and achieve more effective outcomes of interventions.
  • Characterizing social determinants of health in development programs by means of validated psychometric and behavioral instruments is critical to begin deriving digital therapeutics to mitigate this gap effectively.
  • Join this webinar to explore the importance of social determinants of health in achieving optimal health outcomes for cardiometabolic diseases, such as obesity, type 2 diabetes and ischemic heart disease.

HeartBeam Announces Expansion of Its Scientific Advisory Board

Retrieved on: 
Thursday, November 9, 2023
Technology, Medical Devices, Professional Services, Cardiology, Software, Biometrics, Health, Data Analytics, Artificial Intelligence, Medical director, Interventional cardiology, Doctor of Philosophy, Cleveland, AI, International Society, Cleveland Clinic, Baylor Scott & White Medical Center – Temple, Beth Israel Deaconess Medical Center, Physician, American Heart Association, Digital health, Teaching, Electrophysiology, Patient, Ventricular tachycardia, Stanford University, Cardiac catheterization, Atrial fibrillation, Department of Medicine – University of Pamplona, Research, Development, Cornell University, Cordis, United States Air Force Scientific Advisory Board, Digital, Harvard Medical School, Innovation, White, Strategic planning, Stanford University School of Medicine, Arrhythmia, Johnson & Johnson, Weill Cornell Medicine, SAB, Associate, Management, Pharmaceutical industry, Medical device, Medicine, MD, Brigham

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, today announced the expansion of its Scientific Advisory Board (SAB) to include several leading cardiologists.

Key Points: 
  • HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, today announced the expansion of its Scientific Advisory Board (SAB) to include several leading cardiologists.
  • He is a world-renowned expert in interventional cardiology, and an accomplished inventor, entrepreneur, and investment fund founder.
  • “We are honored and pleased to have such a distinguished group of physicians joining our Scientific Advisory Board,” said Branislav Vajdic, Ph.D., CEO and Founder of HeartBeam.
  • “HeartBeam will benefit tremendously from the input of these leaders in interventional cardiology, electrophysiology, clinical research, and new technologies.

The Mullings Group Acquires M. J. Moore & Associates and Names Michael Moore Partner

Retrieved on: 
Wednesday, November 1, 2023
Associate, Digital, Arm, TMG, Interventional cardiology, Human, Medtech, Organization, Acquisition, Attention, Multimedia, Life, Dragonfly, Digital health, Marketing, Johnson & Johnson, Medtronic, Information technology, Partner

The founder of M. J. Moore & Associates, Michael Moore, will join the TMG team as a Partner and continue building companies and careers within our industries.

Key Points: 
  • The founder of M. J. Moore & Associates, Michael Moore, will join the TMG team as a Partner and continue building companies and careers within our industries.
  • The search firm is responsible for more than 8,000 successful searches with over 800+ clients ranging from multi-billion-dollar companies to emerging tech startups worldwide.
  • He began his career at Johnson & Johnson and then spent time in the Interventional Cardiology business unit at Medtronic.
  • "I could not be more excited about joining the exceptional team at The Mullings Group (TMG).

Laguna Tech USA Announces Newly Designed Heart Valves with Advanced Engineering Successfully Implanted in First-in-Human Clinical Trial

Retrieved on: 
Tuesday, October 24, 2023
University, Patient, Trial of the century, Interventional cardiology, Heart, Aortic valve, Instituto Nacional General José Miguel Carrera, ALPHA, Tricuspid valve, Engineering, Aortic regurgitation, ZETA, TAVI, Medical imaging, Medical device

New heart valves, ALPHA and ZETA, designed to provide flexibility and optionality regardless of high, low or zero calcification status

Key Points: 
  • New heart valves, ALPHA and ZETA, designed to provide flexibility and optionality regardless of high, low or zero calcification status
    Patients with aortic regurgitation achieve complete resolution of regurgitation immediately following procedure.
  • To date, two patients have been successfully treated in the Alpha Aortic Valve study, with both achieving complete resolution of aortic regurgitation immediately following the procedure, which has been maintained at the 30-day follow-up examination.
  • The ZETA system is a novel balloon-expandable transcatheter valve with six expanding arms and a low profile covered delivery system.
  • The feasibility study is being conducted at the Instituto Nacional de Torax in Santiago, Chile, and Tbilisi Heart and Vascular Clinic in Georgia.

TCT 2023: Six-Month Clinical Data from DESyne® BDS Plus Randomized Controlled Trial (RCT) Support Safety and Effectiveness of World’s First Site-Specific Antithrombotic Drug Therapy

Retrieved on: 
Wednesday, October 25, 2023
Research, Surgery, Medical Devices, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, Elixir, Medicine, Interventional cardiology, Safety, TLF, TCT, Automotive Supplier Innovation Program, RCT, Randomized controlled trial, Pharmaceutical industry, Pottery

At six months, TLF rate was 1.0% for DESyne BDS Plus and 8.2% (p=0.035; 95%CI, -14.8% to -1.3%) for the durable polymer DES.

Key Points: 
  • At six months, TLF rate was 1.0% for DESyne BDS Plus and 8.2% (p=0.035; 95%CI, -14.8% to -1.3%) for the durable polymer DES.
  • No definite or probable stent thrombosis, target vessel myocardial infarction or cardiovascular deaths were observed with DESyne BDS Plus study device.
  • The DESyne BDS Plus RCT is a prospective, multicenter, randomized, single-blind study of 202 patients across 14 sites.
  • A pharmacokinetic clinical sub-study was conducted to assess the blood pharmacokinetics of sirolimus, rivaroxaban and argatroban eluted from the DESyne BDS Plus device after implantation.

GE HealthCare Announces New Innovations and Collaborations in Image Guided Therapy as part of TCT2023 Cardiology Care Pathway Showcase

Retrieved on: 
Monday, October 23, 2023
Research, Medical Devices, Technology, Hospitals, Clinical Trials, Science, Surgery, Cardiology, Biotechnology, Other Technology, Other Science, Health, Peter Hancock (professor), Anatomy, 3D, System, BMI, Heart, Life, Interventional cardiology, Prevalence, Rotation, Acquisition, Multimedia, CVD, Radiology, GE, Ecosystem, Freedom, Pulse, CV, Workflow, GE HealthCare, Somatosensory system, TCT, Stent, Cath, Patient, Boston Scientific, Diagnosis, Cardiovascular disease, Pharmaceutical industry, Medical imaging, Allia

Allia IGS Pulse was designed to improve workflow for the diagnosis and treatment of cardiovascular diseases in interventional cardiology.

Key Points: 
  • Allia IGS Pulse was designed to improve workflow for the diagnosis and treatment of cardiovascular diseases in interventional cardiology.
  • Building on the recent 510(k) clearance of the Allia IGS Pulse system, GE HealthCare will introduce new technologies and solutions at TCT2023 designed to further transform the capabilities of this platform, as well as image guided therapy in cardiology care.
  • In addition to the company’s interventional cardiology showcase at TCT2023, GE HealthCare will also feature the recently launched Vscan Air SL - a wireless handheld ultrasound device for rapid assessments of cardiac and vascular patients.
  • To learn more about GE HealthCare this year at the Transcatheter Cardiovascular Therapeutics (TCT) 2023 conference (TCT) click here.

Anumana Appoints Maulik Nanavaty as CEO

Retrieved on: 
Thursday, October 19, 2023
Cardiology, Software, Health, Artificial Intelligence, Medical Devices, Data Management, Hospitals, Technology, FDA, ECG, R. Aravamudan, Interventional cardiology, Heart, Automated ECG interpretation, Multimedia, Mayo Clinic, Growth, Pharmacy, Partnership, DSM-IV codes, Baxter International, Reema Nanavaty, University, Algorithm, Therapy, Champaign–Urbana metropolitan area, Management, Medical device, Boston Scientific

Anumana, Inc ., a leading AI-driven health technology company and portfolio company of nference , today announced that Maulik Nanavaty has joined Anumana as chief executive officer and member of the Board of Directors.

Key Points: 
  • Anumana, Inc ., a leading AI-driven health technology company and portfolio company of nference , today announced that Maulik Nanavaty has joined Anumana as chief executive officer and member of the Board of Directors.
  • Murali Aravamudan, co-founder of Anumana and nference, has transitioned to executive chairman of the Anumana Board of Directors while continuing as CEO of nference.
  • Nanavaty will lead Anumana through a period of growth as the company begins deploying and commercializing its multi-indication ECG-AI platform technology.
  • View the full release here: https://www.businesswire.com/news/home/20231019420956/en/
    Maulik Nanavaty has joined Anumana as chief executive officer and member of the Board of Directors.

Supira Medical's Next Generation Percutaneous Ventricular Assist Device (pVAD) System to be Highlighted in a Live Case and Multiple Sessions at the Upcoming TCT 2023 Conference

Retrieved on: 
Friday, October 20, 2023
Exhibition, PDT, Innovation, Interventional cardiology, Use, Physician, Complex, Coronary, Cardiogenic shock, CS, Early, HCPCS Level 2, Coronary artery disease, LOS, Instituto Nacional de Medicina Genómica, Heart Institute, University of São Paulo, Cost, TCT, Paulo, Patient, Medical device, Pharmaceutical industry

LOS GATOS, Calif., Oct. 20, 2023 /PRNewswire/ -- Supira Medical, Inc., a Shifamed portfolio company, announced today that the company's percutaneous ventricular assist device (pVAD) will be showcased in multiple sessions, including a live case presentation, during the 2023 Transcatheter Cardiovascular Therapeutics (TCT) conference taking place October 23-26 in San Francisco, CA.

Key Points: 
  • "We are extremely pleased to have the Supira System included in several outlets of the program this year," commented Dr. Nitin Salunke, President and CEO of Supira Medical.
  • "Thank you to the TCT committee for showcasing Supira in a live case presentation where we can demonstrate how our innovative technology's low profile and high continuous flow has the potential to offer significant advantages for physicians and patients requiring hemodynamic support."
  • The live case presentation from the Instituto do Coracao (InCor) in São Paulo, Brazil will take place at 11:45am PDT in the Coronary Theater, Hall F on the Exhibition Level of Moscone North.
  • Following the company's first-in-human experience, Supira Medical has expanded its clinical program, initiating a feasibility study in São Paulo, Brazil.